Sold as Veregen. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Sinecatechins (sold as Veregen), first approved Oct 31, 2006, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Veregen | Part D | $190K | -15% | 62 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic KeratosisActinic Keratosis of Face and Scalp · Aresus Pharma GmbH | Phase 3 | Recruiting | Aug 22, 2025 |
| To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close MonitoringProstate Carcinoma · ECOG-ACRIN Cancer Research Group | Phase 2 | Active, not recruiting | Oct 22, 2020 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Oct 31, 2006 | VeregenNDA 21902 · New molecular entity | Ani Pharms | 12 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
